View More Recent Stories
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Crinetics Pharmaceuticals (CRNX) Appoints Isabel Kalofonos as Chief Commercial Officer
-
Crinetics Pharmaceuticals (CRNX) Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
-
Crinetics (CRNX) PT Raised to $81 at H.C. Wainwright
-
Piper Sandler Reiterates Overweight Rating on Crinetics (CRNX)
-
Crinetics Pharmaceuticals (CRNX) Prices Upsized 10M Share Offering at $50/sh
-
After-hours movers: Astera Labs, Saratoga Investment, Kezar Life Sciences, and more
-
Crinetics Pharmaceuticals (CRNX) Announces Proposed Public Offering of Common Stock
-
Piper Sandler Reiterates Overweight Rating on Crinetics (CRNX)
-
Crinetics Pharmaceuticals (CRNX) Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
Crinetics Pharmaceuticals (CRNX) Misses Q2 EPS by 8c
-
Piper Sandler Reiterates Overweight Rating on Crinetics (CRNX)
-
Piper Sandler Reiterates Overweight Rating on Crinetics (CRNX)
-
Crinetics Pharmaceuticals (CRNX) +2200 September 50 calls trade at 50c
-
Oppenheimer Reiterates Outperform Rating on Crinetics (CRNX)
-
Crinetics Pharmaceuticals (CRNX) Files Mixed Shelf

